Skip to main content
PCI Biotech Holding logo

PCI Biotech Holding — Investor Relations & Filings

Ticker · PCIB ISIN · NO0010405640 LEI · 5967007LIEEXZXFIGG77 OL Manufacturing
Open in API
Filings indexed 752 across all filing types
Latest filing 2019-04-30 Report Publication Anno…
Country NO Norway
Listing OL PCIB

About PCI Biotech Holding

https://www.pcibiotech.no/

PCI Biotech Holding is a biopharmaceutical company developing therapeutic products based on its proprietary Photochemical Internalization (PCI) technology. This platform is a drug and nucleic acid delivery system designed to enhance the intracellular delivery of therapeutic molecules. The company's development programs are focused on applications in immunotherapy, dermatology, and bioprocessing for the manufacturing of viral vectors. A primary therapeutic area for the technology is cancer, where it aims to improve the efficacy of novel and existing treatments.

Recent filings

Filing Released Lang Actions
PCI Biotech: Invitation to first quarter 2019 result presentation
Report Publication Announcement Classification · 98% confidence The document is titled 'PCI Biotech: Invitation to first quarter 2019 result presentation'. It explicitly invites stakeholders to a presentation for the first quarter 2019 results and states that 'The interim report and the presentation will be available on www.newsweb.no and on the company's webpage... on 8 May 2019.' Since the document itself is an invitation/announcement about the upcoming release and presentation of the interim report, and not the comprehensive interim report itself, it fits the definition of a Report Publication Announcement (RPA). The document length (2824 chars) is also short, supporting the RPA classification over the full Interim Report (IR).
2019-04-30 English
PCI Biotech: Annual Report 2018
Report Publication Announcement Classification · 99% confidence The document text explicitly states: 'The Board of Directors of PCI Biotech Holding ASA has approved the Annual Report 2018 and the report is attached.' It also includes a link labeled '2018 Annual report PCI Biotech Holding ASA' under an 'Attachment' section. The document length is short (2538 chars) and its primary function is to announce the availability of the full Annual Report, rather than being the report itself. According to Rule 2 (The 'MENU VS MEAL' Rule), when a short document announces that a report has been published or is attached, it should be classified as a Report Publication Announcement (RPA).
2019-04-09 English
PCI Biotech: Annual Report 2018
Annual Report Classification · 100% confidence The document is explicitly titled 'ANNUAL REPORT 2018' for PCI Biotech Holding ASA. It contains comprehensive sections including an introduction, board of directors report, corporate governance, and references to financial statements and auditor reports. It is a full-length annual report, not an announcement or a summary. FY 2018
2019-04-09 English
PCI Biotech: Annual Report 2018
Report Publication Announcement Classification · 100% confidence The document is a short announcement (2249 characters) stating that the Annual Report 2018 has been approved and is attached via a link. Per the 'Menu vs Meal' rule, this is an announcement of a report rather than the report itself. Therefore, it is classified as a Report Publication Announcement (RPA). FY 2018
2019-04-09 English
PCI Biotech: Final confirmation of successful safety read-out in the Phase I Extension study
Legal Proceedings Report Classification · 99% confidence The document is a press release dated April 8, 2019, announcing the 'final confirmation of successful safety read-out for the Phase I Extension study' for a cancer therapeutic (fimaChem). It details clinical trial results, patient numbers, survival data, and outlines the next steps for the pivotal RELEASE study, including expected timelines for regulatory submissions (EMA/FDA). This type of announcement, focusing on clinical trial progress and immediate next steps, is characteristic of an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it is a specific, material update on clinical progress rather than a comprehensive financial report (10-K or IR) or a general announcement about a report being published (RPA), it fits best as an Earnings Release (ER) if it's tied to a reporting period, or RNS if it's purely operational/clinical news. Given the nature of clinical trial updates being frequently released alongside or instead of quarterly earnings highlights, ER is a strong candidate. However, since it is a specific clinical update that doesn't explicitly mention quarterly financials or earnings figures, and it is a material event disclosure, the most appropriate general category for significant, non-standard operational/clinical news that must be disclosed is Regulatory Filings (RNS), or potentially a specific type of operational update. Reviewing the definitions, it is not a CT, IP, or MDA. It is a material announcement of clinical progress. In many databases, significant clinical trial updates that are not part of a formal quarterly report are classified under general regulatory announcements. Given the options, and since it's a specific, material operational update, RNS (Regulatory Filings - fallback) is appropriate, but ER (Earnings Release) often covers key operational highlights that drive investor interest. Since it focuses heavily on clinical data and future study initiation rather than summarizing overall financial performance for a period, RNS is safer, but let's check if it aligns with ER. ER is defined as 'Initial announcement of quarterly/periodical financial results (key highlights only)'. This is a key operational highlight. If this were released alongside quarterly results, it would be part of the ER package. Without explicit quarterly context, RNS is the safest catch-all for material, non-standard disclosures. However, clinical trial updates are often grouped with ERs. Given the high impact nature of a successful safety read-out, I will classify it as an Earnings Release (ER) as it serves as a key performance indicator update, which is often bundled with ERs, even if financial figures are sparse. If RNS was chosen, it would be a fallback. Let's re-evaluate: It is a press release announcing a major clinical milestone. This is a common type of announcement that falls under general regulatory disclosure requirements (like the Norwegian Securities Trading Act mentioned at the end). Therefore, RNS (Regulatory Filings) is the most accurate general category for material, non-standard operational news that isn't a full report or a management discussion.
2019-04-08 English
PCI Biotech: Resignation of Chief Business Development Officer
Board/Management Information Classification · 98% confidence The document is a short announcement dated February 28, 2019, stating that the Chief Business Development Officer (CBDO) of PCI Biotech has resigned. This directly concerns a change in senior management personnel. According to the definitions, 'Board/Management Information (Code: MANG)' covers the 'Announcement of changes in the company's board of directors or senior management.' The document length is short (3148 chars) and it is a direct announcement, not a comprehensive report, confirming the classification as a management change announcement.
2019-02-28 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.